[Action of injected disopyramide on ventricular arrhythmias and atrioventricular conduction].
The authors have studied the bathmotropic and dromotropic effects of intravenous injection of 100 mg of disopyramide, the therapeutic dose being 1 to 2 mg/kg. Out of the 28 severe arrhythmias studied, it was the ventricular extrasystoles which benefited most from treatment (79% completely successful, while there was a lesser degree of success in treating the ventricular tachycardias (35% completely successful, 30% partially successful). The negative dromotropic effect of injected disopyramide on sub-nodal conduction was studied by an endocavitary technique in 10 patients presenting with a spontaneous onset of disordered intracardiac conduction; the effects were moderate. With the exception of 4 cases who sustained complications involving rhythm and haemodynamics, the clinical and cardiovascular tolerance of patients to the drug appeared to be satisfactory.
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000494:pharmacology* / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006327:Heart Block / Q000188:drug therapy; D006329:Heart Conduction System / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects*; D006352:Heart Ventricles; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000494:pharmacology*; D013610:Tachycardia / Q000188:drug therapy
D011725:Pyridines; D004206:Disopyramide
Action du Disopyramide injectable sur les arythmies ventriculaires et sur la conduction auriculo-ventriculaire